Form 4: NewAmsterdam Pharma Chief Scientific Officer Acquires 200,000 Stock Options

Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NewAmsterdam Pharma, was granted options to purchase 200,000 ordinary shares.

Summary

• Johannes Jacob Pieter Kastelein, the Chief Scientific Officer of NewAmsterdam Pharma Co N.V., was granted options to purchase 200,000 ordinary shares.
• The options have an exercise price of $25.96 per share.
• The options vest over a four-year period, with 25% vesting on January 2, 2026, and the remaining 75% vesting in equal monthly installments over the following three years.
• The vesting is contingent upon Mr. Kastelein's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If Mr. Kastelein leaves the company before the options fully vest, he may forfeit some or all of the options.

Future Outlook

The options will vest over the next four years, subject to the continued service of the Chief Scientific Officer.

Industry Context

The granting of stock options is a common practice in the pharmaceutical industry to incentivize key executives and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech and pharmaceutical industries.
• Vesting schedules, such as the four-year schedule described, are also common to encourage long-term commitment.
• The specific terms of the options, such as the exercise price and vesting schedule, are generally tailored to the individual company and executive.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, vesting, NAMS, NewAmsterdam Pharma, Johannes Jacob Pieter Kastelein